Novavax Could Deliver 100M Covid-19 Vaccine Doses By End of Year, Says R&D Head

The video discusses the progress and challenges in developing a COVID-19 vaccine. It highlights the validation of technology by Cepi, the timeline for vaccine availability, and the distribution strategy focusing on first responders and at-risk populations. The speaker emphasizes global cooperation and manufacturing plans, addressing potential challenges and the importance of funding and execution in clinical trials.

What is the primary goal of the collaboration with Seppi?

• To validate the technology

• To delay vaccine production

• To compete with other companies

• To reduce manufacturing costs

By when does the company aim to deliver 100 million doses?

• By the end of the year

• In two years

• In five years

• By next month

What is the expected timeline for vaccine deployment according to the speaker?

• Before the end of the year

• In five years

• In 18 months

• Within a decade

What is the company's confidence based on regarding the vaccine's safety?

• Lack of human trials

• Unproven technology

• Previous experience with similar technology

• No data available

Who are expected to receive the vaccine first in the US?

• Tourists

• Politicians

• Frontline workers

• Children

What is the main concern regarding the distribution of vaccines globally?

• No demand

• Excessive supply

• Free market dynamics

• Lack of interest

What is the role of Cepi in the vaccine distribution process?

• To limit production

• To delay manufacturing

• To provide financial support

• To restrict global access

What is the company's strategy to ensure global vaccine supply?

• Centralized manufacturing

• Multiple regional manufacturing sites

• Exclusive US production

• Limited production capacity

What is a significant challenge in the vaccine development process?

• Lack of competition

• Execution of clinical trials

• Excessive funding

• No regulatory oversight

What has been a major barrier to developing a respiratory vaccine?

• Lack of scientific knowledge

• Insufficient funding

• Too many vaccines available

• No interest from the public